Fifteen Israeli companies are expected to come to Charleston, South Carolina, May 6-7, along with major US stakeholders in Neurotechnology to explore business and research relationships at the US-Israel Neurotechnology Business Exchange. Hosted by the Medical University of South Carolina (MUSC) in Charleston, South Carolina, the event will offer a focused opportunity for them to present their technologies and have pre-arranged meetings with leading pharmaceutical, diagnostic, and device companies, healthcare institutions, and investors in North America with the goal of fostering joint venture R&D, investment, and marketing alliances.
Organized by the Medical Committee and the South Carolina-Israel Collaboration of the American-Israel Chamber of Commerce, Southeast Region and the BIRD Foundation and Israel Brain Technologies in Israel, the two-day event is built on the premise that the United States remains one of the major hubs for innovation, development, and commercialization of new products for the diagnosis and treatment of brain disorders, and Israeli companies working in this field have seen that the presence in the US is a critical step for success with its innovation and proven track record in fields such as computer science, nanotechnology and brain research.
McKinsey & Company conducted an analysis of the Israel brain research and technology landscape, and the report indicated that Israel is uniquely positioned to develop leadership in two areas of brain communication: the Brain Machine Interface (BMI) and therapeutic neuro-stimulation devices, and that Israeli companies working in this field must have a presence in the US as a critical step for success. Focus areas for the business exchange will include Brain Disorders and Novel Approaches (Diagnosis, Treatment, and Practice).
In addition to the MUSC, other sponsors to date include Womble Carlyle, Israel Economic Mission, The InterTech Group, CRDA, Consulate General of Israel to the Southeast; IATI, SCBio, University of South Carolina, and Clemson University. Additional sponsorships are available, and those interested are urged to contact Tom Glaser (firstname.lastname@example.org).